Rencofilstat

Rencofilstat is Hepion Pharmaceuticals' oral pan-cyclophilin inhibitor for MASH (formerly NASH) patients with advanced fibrosis. The Phase 2b ASCEND-NASH trial (NCT05461105) targeted 336 F2/F3 patients (moderate-to-severe liver scarring on a 0-4 stage scale, below cirrhosis) with ≥60% F3 enrollment requirement; the trial was wound down in April 2024 with 151 subjects randomized, and the published Liver International 2025 readout reports a subset of n=70 suspected ≥F3 patients dosed 120 days [1][2]. The primary endpoint was change in HepQuant SHUNT - a non-invasive test of liver function that measures portal-systemic shunting via cleared oral test compounds - rather than the paired biopsy histology FDA requires for accelerated MASH approval [3]. With Madrigal's resmetirom approved March 2024 and semaglutide hitting both ESSENCE Phase 3 co-primary endpoints (62.9% steatohepatitis resolution, p<0.001) [3][10], the competitive bar in MASH has moved sharply higher. Hepion disclosed $2.6M cash as of 31 March 2026 with substantial-doubt going-concern language and runway into Q3 2026 [4] - the asset's path forward requires partnership or acquisition, not internal Phase 3 funding.

Novel small molecule, no prior approval anywhere. Originally CRV431/CPI-431 from Ciclofilin Pharmaceuticals, picked up by Hepion (formerly ContraVir, ticker HEPA). Two completed clinical studies anchor the data package: a Phase 2a in F2/F3 NASH reporting non-invasive biomarker movement [5], and the Phase 2b ASCEND-NASH (NCT05461105), originally designed for n=336 across four arms but paused at 151 randomized in April 2023 and wound down April 2024 [2]. The published Harrison et al. 2025 Liver International analysis covers n=70 suspected ≥F3 patients across the three dose arms plus placebo, dosed 120 days, with HepQuant DuO/SHUNT readouts at baseline, Day 60, and Day 120 [1]. A radiolabeled ADME study (NCT05737433) closed out the human pharmacology package [6]. No FDA breakthrough therapy, fast track, or orphan drug designations are public for this asset. That is itself a signal - drugs with clean Phase 2 efficacy in MASH typically secure at least fast track given the unmet need backdrop. No registrational Phase 3 has been initiated. With $2.6M cash on 31 March 2026, going-concern language, and runway only into Q3 2026 [4], the realistic path forward requires a partner or asset sale, not a micro-cap sponsor running a multi-year biopsy-confirmed Phase 3 on its own balance sheet.

Cyclophilins are proteins that help other proteins fold into the right shape by flipping a specific kink in their backbone - cis-trans isomerization of proline. Three of them matter for liver biology: cyclophilin A sits in the cytoplasm and also gets secreted, where it acts as an inflammatory signal that pulls immune cells to damaged tissue; cyclophilin B handles folding in the secretory pathway; cyclophilin D lives in mitochondria and gates a stress valve called the permeability transition pore. When that pore stays stuck open under metabolic stress, the cell dies. In NASH, hepatocytes (liver cells) load up with fat, get inflamed, then die in ways that activate stellate cells, which lay down scar tissue. Rencofilstat is characterized by Hepion as a pan-cyclophilin inhibitor binding CypA, CypB, and CypD - this tri-target profile is sponsor-reported from preclinical biochemistry and has not been independently validated in a peer-reviewed mechanism paper at the time of writing [7]. The bet is that hitting CypD reduces hepatocyte death, hitting CypA dampens the inflammatory recruitment signal, and hitting CypB tweaks the unfolded protein response - together breaking the fat-to-inflammation-to-fibrosis loop. Validation is mixed. Cyclosporine A is the original cyclophilin binder and an approved immunosuppressant - its immunosuppression comes from then engaging calcineurin to suppress T cells. Rencofilstat is non-immunosuppressive because it does not recruit calcineurin [5]. The cleanest prior human signal for non-immunosuppressive cyclophilin inhibition in liver disease came from alisporivir in hepatitis C, which was placed on FDA clinical hold after pancreatitis cases including one death in the VITAL-1 program [8]. MASH-specific human validation rests on Hepion's own small Phase 2a and Phase 2b biomarker datasets - no biopsy-confirmed fibrosis improvement has been published.

ASCEND-NASH (NCT05461105) was designed to enroll 336 patients with F2/F3 NASH (≥60% F3) across three dose arms (75, 150, 225 mg daily) plus placebo for 12 months, but was paused at 151 randomized in April 2023 and wound down in April 2024 [2]. The published readout (Harrison 2025 Liver International, n=70 suspected ≥F3 subjects dosed 120 days) reports a significant decrease in portal-systemic shunting (SHUNT%) at Day 60 (−1.67%, p=0.0156) and Day 120 (−1.55%, p=0.0441) across all subjects pooled, and a significant improvement in Disease Severity Index in the 225 mg arm (mean change −1.61, p=0.0190), with 56% responders at the high dose. Patients with baseline DSI >18.3 (more severe disease) showed the largest improvements [1]. The endpoint choice is the design problem. FDA's accelerated approval pathway for NASH/MASH requires either NASH resolution without fibrosis worsening or fibrosis improvement without NASH worsening, both measured by biopsy [3]. HepQuant DuO is being developed as a non-invasive correlate, but it is not a qualified regulatory endpoint. A directionally positive readout here generates a publication and a thesis for a Phase 3, not a registrational dataset. The truncated sample (n=70 in the published subset; the full 336-patient enrollment was never completed) and 120-day dosing window are tight for fibrosis modification. Madrigal's MAESTRO-NASH ran 52 weeks for its histologic primary, and fibrosis-targeted assets generally need 18-24 months of treatment to move biopsy scores. No paired pre/post biopsy fibrosis data from ASCEND-NASH has been published - the readout is functional/biomarker only.

Our model gives this drug a 5% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 2 drugs in this area - about 23% - then adjusts based on ten specific facts about the trial and the sponsor. The number is pulled down mainly by heavier-than-usual blinding, a weak sponsor approval record, limited earlier-phase results, and a randomized design. The remaining factors are close to average for this stage and don't move the estimate much either way.

Efficacy risk is the headline. The Phase 2b primary endpoint (HepQuant DuO/SHUNT) is a non-invasive surrogate not qualified by FDA for accelerated approval in MASH. The published Day 120 data hit nominal statistical significance on SHUNT% and on DSI at the 225 mg dose [1], but the trial enrolled only 151 of a planned 336 subjects and the readout is biomarker-only, not histology [2]. A positive readout buys a Phase 3 story, not a registrational endpoint. Safety risk is mechanism-adjacent. Alisporivir (Debio-025), another non-immunosuppressive cyclophilin inhibitor developed for hepatitis C, was placed on FDA clinical hold after three pancreatitis cases including one death in the VITAL-1 program [8]. Cyclophilin inhibition intersects with mitochondrial physiology (CypD) and immune signaling (CypA), making dose-dependent off-target signals a real concern at registrational exposures. The published Phase 2a reported acceptable tolerability at tested doses [5], but small datasets do not rule out lower-frequency events. Competitive risk has shifted dramatically in the past 18 months. Madrigal's resmetirom got accelerated approval in March 2024 - the first MASH drug across the line and now the de facto standard of care [3]. Boehringer/Zealand's survodutide and Akero's efruxifermin are posting strong Phase 2/3 data. Semaglutide hit both ESSENCE Phase 3 co-primary endpoints (NEJM 2025) [10]. A Phase 3 cyclophilin inhibitor reading out years from now launches into a stack of approved and late-stage mechanisms. Company risk is sharpest. Hepion's Q1 2026 10-Q discloses $2.6M cash, $0 revenue, substantial-doubt going-concern language, and runway only into Q3 2026 [4]. A micro-cap biotech with no commercial product, no partnered program, one wound-down Phase 2b asset, and an ongoing restructuring is operating on the runway, not the science. IP position is not disclosed in detail in public filings - composition-of-matter expiry and formulation patents materially affect partnership valuation but are not summarized in standard sponsor materials.

Watch but discount. The science has a real biological rationale - multi-target cyclophilin inhibition fits MASH pathobiology, and the alisporivir precedent shows the class can move liver biology in humans. The data package and the company position both argue for skepticism. The most interesting strategic angle is what the writeup has been understating: cyclophilin inhibition is mechanistically orthogonal to GLP-1 metabolic effects and FGF21 hormonal effects. In a market where the standard of care is moving toward weight-loss-driven MASH resolution, an anti-fibrotic mitochondrial-protective add-on has a credible combination thesis - particularly in patients who plateau on GLP-1 fibrosis benefit. This is the BD pitch that survives in a resmetirom-and-semaglutide world. Whether it's worth funding a 24-month Phase 3 to test is a different question. The signal to watch is not the next Hepion press release. It is whether anyone with deep pockets partners or acquires the asset before the cash runs out. Concrete signals worth tracking: (1) full paired-biopsy data, not only HepQuant readouts, from the wound-down ASCEND-NASH cohort; (2) any partnership, M&A, or restructuring language on Hepion's 8-K feed [4]; (3) reverse-merger or delisting risk language in the next 10-Q; (4) FDA qualification status updates on HepQuant DuO as a MASH surrogate; (5) any combination-trial signaling with a GLP-1 or FGF21 sponsor. Check back after Hepion's next quarterly disclosure (Q2 2026 10-Q expected August) or any partnership announcement. Until then this is science-interesting and commercially-strained - a cheap option, not a position.